-
Loading metrics
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials
-
Naveed Sattar ,
Roles Writing – review & editing
* E-mail: Naveed.sattar@glasgow.ac.uk
Affiliation School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom
⨯ - Reshmi Srinath,
- Luis-Emilio García-Pérez,
- Clare J. Lee,
- Chrisanthi A. Karanikas,
- Xinyue Chen,
- Arian Plat
https://orcid.org/0000-0002-1604-2593
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials
- Naveed Sattar,
- Reshmi Srinath,
- Luis-Emilio García-Pérez,
- Clare J. Lee,
- Chrisanthi A. Karanikas,
- Xinyue Chen,
- Arian Plat
x
- Published: August 13, 2026
- https://doi.org/10.1371/journal.pone.0345032